SYBX
$2.27
Synlogic
($.10)
(4.22%)
SYBX
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.28)
Revenue:  $0.33 Mil
Wednesday
Feb 9
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SYBX reports earnings?
Beat
Meet
Miss

Where is SYBX's stock price going from here?
Up
Flat
Down
Stock chart of SYBX
Analysts
Summary of analysts' recommendations for SYBX
Score
Grade
Pivots
Resistance
$2.59
$2.52
$2.39

$2.32

Support
$2.19
$2.12
$1.99
Tweet
Growth
Description
Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts.